These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 11713894)

  • 1. In vitro susceptibility and eradication of Chlamydia pneumoniae cardiovascular strains from coronary artery endothelium and smooth muscle cells.
    Gieffers J; Solbach W; Maass M
    Cardiovasc Drugs Ther; 2001; 15(3):259-62. PubMed ID: 11713894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment.
    Gieffers J; Füllgraf H; Jahn J; Klinger M; Dalhoff K; Katus HA; Solbach W; Maass M
    Circulation; 2001 Jan; 103(3):351-6. PubMed ID: 11157684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eradication of Chlamydia pneumoniae from coronary artery endothelium.
    Hammerschlag MR
    Cardiovasc Drugs Ther; 2002 Mar; 16(2):167; author reply 169. PubMed ID: 12090910
    [No Abstract]   [Full Text] [Related]  

  • 4. In vitro susceptibilities of Chlamydia pneumoniae isolates from German patients and synergistic activity of antibiotic combinations.
    Freidank HM; Losch P; Vögele H; Wiedmann-Al-Ahmad M
    Antimicrob Agents Chemother; 1999 Jul; 43(7):1808-10. PubMed ID: 10390251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro susceptibilities of Chlamydia pneumoniae strains recovered from atherosclerotic coronary arteries.
    Gieffers J; Solbach W; Maass M
    Antimicrob Agents Chemother; 1998 Oct; 42(10):2762-4. PubMed ID: 9756794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of telithromycin, a new ketolide, against Chlamydia pneumoniae.
    Miyashita N; Fukano H; Niki Y; Matsushima T
    J Antimicrob Chemother; 2001 Sep; 48(3):403-5. PubMed ID: 11533006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in the management of Chlamydia pneumoniae infections.
    Hammerschlag MR
    Expert Rev Anti Infect Ther; 2003 Oct; 1(3):493-503. PubMed ID: 15482145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae.
    Hammerschlag MR; Qumei KK; Roblin PM
    Antimicrob Agents Chemother; 1992 Jul; 36(7):1573-4. PubMed ID: 1324650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isolation of Chlamydophila pneumoniae from atheromas of the carotid artery and their antibiotics susceptibility profile.
    Cuffini C; Alberto Guzmán L; Villegas N; Eduardo Alonso C; Martínez-Riera L; Rodríguez-Fermepín M; Carolina Entrocassi A; Pilar Adamo M; Pedranti M; Zapata M
    Enferm Infecc Microbiol Clin; 2006 Feb; 24(2):81-5. PubMed ID: 16545314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Chlamydial infections: 2014 update.
    Kohlhoff SA; Hammerschlag MR
    Expert Opin Pharmacother; 2015 Feb; 16(2):205-12. PubMed ID: 25579069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Choice of antimicrobial drug for infections caused by Chlamydia trachomatis and Chlamydophila pneumoniae].
    Zele-Starcević L; Plecko V; Budimir A; Kalenić S
    Acta Med Croatica; 2004; 58(4):329-33. PubMed ID: 15700690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of short-term antibiotic treatment on Chlamydia pneumoniae and peripheral endothelial function.
    Kuvin JT; Gokce N; Holbrook M; Hunter LM; Patel AR; Sliney KA; Craven DE; Grayston JT; Keaney JF; Karas RH; Vita JA
    Am J Cardiol; 2003 Mar; 91(6):732-5. PubMed ID: 12633811
    [No Abstract]   [Full Text] [Related]  

  • 13. [Arteriosclerosis as a sequela of chronic Chlamydia pneumoniae infection].
    Stille W; Dittmann R
    Herz; 1998 May; 23(3):185-92. PubMed ID: 9646100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro infection and pathogenesis of Chlamydia pneumoniae in endovascular cells.
    Quinn TC; Gaydos CA
    Am Heart J; 1999 Nov; 138(5 Pt 2):S507-11. PubMed ID: 10539860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atherogenetically relevant cells support continuous growth of Chlamydia pneumoniae.
    Maass M; Gieffers J; Solbach W
    Herz; 2000 Mar; 25(2):68-72. PubMed ID: 10829241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucocorticoids increase in vitro and in vivo activities of antibiotics against Chlamydophila pneumoniae.
    Caronzolo D; Lucini V; Pannacci M; Grosso S; Colleoni F; Fraschini F; Scaglione F
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4878-81. PubMed ID: 15561871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of azithromycin on endothelial function of patients with coronary artery disease and evidence of Chlamydia pneumoniae infection.
    Hammerschlag MR
    Circulation; 2002 Oct; 106(15):e65-6; author reply e65-6. PubMed ID: 12370232
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of macrolide antibiotics on human endothelial cells activated by Chlamydia pneumoniae infection and tumor necrosis factor-alpha.
    Uriarte SM; Molestina RE; Miller RD; Bernabo J; Farinati A; Eiguchi K; Ramirez JA; Summersgill JT
    J Infect Dis; 2002 Jun; 185(11):1631-6. PubMed ID: 12023769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth cycle-dependent pharmacodynamics of antichlamydial drugs.
    Siewert K; Rupp J; Klinger M; Solbach W; Gieffers J
    Antimicrob Agents Chemother; 2005 May; 49(5):1852-6. PubMed ID: 15855506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary prevention of atherosclerosis through chlamydia pneumoniae eradication (SPACE Trial): a randomised clinical trial in patients with peripheral arterial disease.
    Vainas T; Stassen FR; Schurink GW; Tordoir JH; Welten RJ; van den Akker LH; Kurvers HA; Bruggeman CA; Kitslaar PJ
    Eur J Vasc Endovasc Surg; 2005 Apr; 29(4):403-11. PubMed ID: 15749042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.